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Clinical factors affecting gefitinib treatment - one institution’s 
experience
Minato, Koichi1 Yoshino, Reiko1 Ishihara, Shin-Ichi2 
1 Gunma Cancer Center, Ota, Japan 2 Isesaki Municipal Hospital, 
Isesaki, Japan 
Purpose: To identify the clinical factors affecting the effectiveness on 
prognosis of advanced non-small-cell lung cancer patients treated with 
geﬁtinib in a practical setting.
Methods: Between August 2002 and December 2004, 80 advanced 
non-small-cell lung cancer patients were treated with geﬁtinib in 
Gunma Prefectural Cancer Center. We retrospectively analysed the 
relationship between clinical factors and response or overall survival. 
The clinical factors included the following: sex, age, smoking status, 
histologic subtype, dermatological toxicity, performance status, and 
treatment status.
Results: The overall response rate was 11.3% (9/80). The response rate 
for adenocarcinoma was 14.8% (8/54) and that for non-adenocarcino-
ma was 3.8% (1/26)(p=.282). In terms of smoking status, the response 
rate of smokers was 4.1% (2/49) and that of non-smokers was 21.4% 
(6/28)(p=.051). The response rate of males was 9.1% (5/55) and that 
of females was 16.0% (4/25)(p=.485). The median overall survival of 
all patients was 8.9 months. Median survival (MS) of females was 15.9 
months, that of males was 6.8 months (p=0.015). As for smoing status, 
the MS of smokers was 6.9 months and that of non-smokers was 15.9 
months (p=0.003). The MS of the patients with skin toxicity was 14.0 
months and for those without skin toxicity was 5.9 months (p=0.0001). 
Good PS patients showed longer suivival compared to the poor PS 
patients (p=0.0002).
Conclusion: Signiﬁcantly longer survival was observed in females, 
non-smokers, PS 0-1and with occurrence of skin toxicity.
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Background: PS 2 or 3 patients are usually excluded from clinical 
trials. Optimal treatment in this setting remains a matter of controversy. 
The aim of this study by Intergroupe Francophone de Cancerologie 
Thoracique (IFCT) was to evaluate 3 monotherapy modalities and bet-
ter understand causes for compromised PS.
Methods: PS 2 or 3 patients with conﬁrmed advanced NSCLC were 
included into a multicenter phase II randomized trial: arm A, geﬁtinib 
(250 mg/day), arm B gemcitabine (1250 mg/m≥, day 1 & 8, every 3 
weeks) and arm C docetaxel (75 mg/m≥, day 1, every 3 weeks). Treat-
ments were maintained until progression or unacceptable toxicity. The 
second-line treatment consisted of: arm A: docetaxel (75 mg/m≥, day 
1, every 3 weeks) and arm B/C: geﬁtinib (250 mg/day). The primary 
endpoint was Progression Free Survival (PFS).
Results: Between December 2004 and February 2007, 117 patients 
were enrolled. Out of the 100 ﬁrst eligible patients, the characteris-
tics were the following: median age 71 years (range 30-79), male 84 
% - female 16 %, PS=2 72 %, PS=3 28 %, adenocarcinoma 52 %, 
squamous cell 25 %, other 23 %. No objective signiﬁcant difference 
could be observed between PS 2 and 3, among clinical and biological 
parameters (table). 35% of PS 2 patients versus 16 % of PS 3 patients 
received a second-line treatment (as deﬁned in the protocol, p=0.12). 
4 fatal events were related to treatment: 3 related to chemotherapy 
attributed to febrile neutropenia and 1 related to geﬁtinib attributed to 
bowel obstruction.
Conclusions: In this study neither comorbidities nor the tumour burden 
could explain the difference observed in the PS. This preliminary anal-
ysis suggests that PS doesn’t seem to have any clinical impact in the 
number of given second-line treatments. The complete results of PFS, 
overall survival and toxicity by arm will be presented at the meeting.
Characteristics TOTAL (n=100) PS 2 (n=72) PS 3 (n=28) p
PATIENT
Age (years) 71 (30-79) 71.5 (30-79) 68.5 (48-79) 0.2
Female 16 13 (18 %) 3 (11 %) 0.58
Charlson Score (range) 1 (0-6) 1 (0-5) 1 (0-6) NS
Haemoglobin (g/dL) 11.7 12.1 11.2 0.09
LDH (IU/L) 406 406 388 0.66
TUMOR BURDEN
Adenocarcinoma 52 37 (51 %) 15 (54 %) 0.96
Stage IV 80 57 (79 %) 23 (82 %) 0.95
Metastatic sites (2+) 27 19 (26 %) 8 (29 %) 0.96
Initial RECIST (mm) 88.5 89.5 78.5 0.62
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Dual retinoid agonists with chemotherapy in advanced non-small-
cell lung cancer
Nandan, Raghu 
Lakewood, CA, USA
Non-small-cell lung cancer (NSCLC) is the most common cause of 
cancer deaths in both women and men. Most patients are diagnosed 
at an advanced stage and have very poor outcomes; better treatments 
are urgently needed. The efﬁcacy of chemotherapy is usually limited; 
therefore several non-cytotoxic targeted therapy agents have been 
recently evaluated, either alone or in combination with chemotherapy. 
Both tretinoin, a retinoic acid receptor (RAR) agonist as well as bex-
arotene (a rexinoid receptor (RXR) agonist have been used in non small 
cell lung cancer both alone and in combination with chemotherapy with 
activity. Also, both have reduced bioavailability with continued dosing. 
Our earlier study with intermittent dosing of tretinoin and chemothera-
py showed activity. This is a preliminary report on the combination of 
brief periods of tretinoin and bexarotene in combination with cisplatin 
and docetaxel based chemotherapy in 12 patients advanced non small 
cell lung cancer. 
The ECOG performance status was 2 in nine patients and 1 in three. 
Four (33%) patients had brain metastases controlled with radiation. 
Nine patients were previously untreated for NSCLC and three had been 
treated with a tyrosine kinase inhibitor before this regimen. 11 patients 
had stage IV disease and one had IIIb disease. 7 were females, 5 were 
